Slideshows Images Quizzes

Indigo Carmine

Last reviewed on RxList: 10/20/2008
Drug Description

INDIGO CARMINE
(indigotindisulfonate sodium) Injection, USP

DESCRIPTION

Each 5 mL contains: 40 mg of Indigotindisulfonate Sodium, in Water for Injection, q.s. pH adjusted, when necessary, with Citric Acid and/or Sodium Citrate.Sterile, nonpyrogenic.

Sufficient Indigo Carmine (indigotindisulfonate) is contained in each 5 mL ampule to permit accurate withdrawal and administration of the full dose.It gives a deep blue solution when dissolved in water.

The structural formula is:

INDIGO CARMINE INJECTION (Indigotindisulfonate Sodium Injection,USP)  Structural Formula Illustration

C16H8N2Na2O8S2............................Molecular Weight 466.35

Indications & Dosage

INDICATIONS

Originally employed as a kidney function test, the chief application of Indigo Carmine (indigotindisulfonate) at present is localizing ureteral orifices during cystoscopy and ureteral catheterization.

DOSAGE AND ADMINISTRATION

Indigo Carmine (indigotindisulfonate) solution is injected either by the intravenous or intramuscular route, and its appearance at the ureteral orifices is watched with the cystoscope in place. The intravenous method is preferred because a 5 mL injection is sufficient.A lesser dosage in infants, children and underweight patients will prevent skin coloration.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

PROTECT FROM LIGHT

Store at controlled room temperature 15°-30°C (59° -86°F).

HOW SUPPLIED

Indigo Carmine (indigotindisulfonate) Injection

NDC 0517-0375-10...............5 mL ampules..............packaged in boxes of 10

AMERICAN REGENT LABORATORIES, INC. Shirley, NY 11967. Rev.7/98. FDA Rev date: n/a

Side Effects & Drug Interactions

SIDE EFFECTS

See "WARNINGS" section.

Drug Abuse And Dependence

Indigo Carmine (indigotindisulfonate) is not a controlled substance listed in any of the Drug Enforcement Administration Schedules.Its use is not known to lead to dependence or abuse.

DRUG INTERACTIONS

No information provided.

Warnings & Precautions

WARNINGS

An occasional idiosyncratic drug reaction may occur. A mild pressor effect may be encountered in some patients. Since precipitation of indigotindisulfonate sodium may occur, Indigo Carmine (indigotindisulfonate) Solution must not be diluted prior to injection or injected with infusion assemblies which were used with other solutions.

PRECAUTIONS

Indigo Carmine (indigotindisulfonate) should be stored in the dark, away from direct light, preferably in the original package.

Pregnancy Category C

Animal Reproduction studies have not been conducted with indigotindisulfonate sodium injection.It is also not known whether indigotindisulfonate sodium injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Indigotindisulfonate sodium injection should be given to a pregnant woman only if clearly needed.

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Indigo Carmine (indigotindisulfonate) is administered to a nursing woman.

Overdosage & Contraindications

OVERDOSE

There are no data available describing the signs, symptoms or laboratory findings accompanying overdosage.

No discernible symptoms of toxicity have been observed in mice with an intravenous dose of 200 mg/kg. After intravenous administration the LD80 was established at 300 mg/kg in mice.

CONTRAINDICATIONS

Indigo Carmine (indigotindisulfonate) is contraindicated in patients who have previously experienced an adverse reaction following its use.

Clinical Pharmacology

CLINICAL PHARMACOLOGY

Indigo Carmine (indigotindisulfonate) is excreted largely by the kidneys, retaining its blue color during passage through the body.

Elimination of the dye begins soon after injection, appearing in the urine within 10 minutes in average cases.The biological half-life is 4 to 5 minutes following intravenous injection. Larger quantities are necessary when intramuscular injection is employed. Appearance time and elimination are delayed following intramuscular injection.

Medication Guide

PATIENT INFORMATION

No information provided. Please refer to the WARNINGS and PRECAUTIONS sections.

FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Health Solutions From Our Sponsors